Filing Flows › Angiodynamics (ANGO) › Q1 FY26
Angiodynamics (ANGO) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Oct 2, 2025
Angiodynamics (ANGO) reported revenue of $75.7M for the first quarter fiscal 2026 (Q1 FY26), +12% from a year earlier and -6% from the quarter before. Operating margin was -14.1%, net loss $10.9M (14.4% of revenue).
Angiodynamics, Q1 FY26: revenue $75.7M (+12% year over year), operating margin -14.1%, net loss $10.9M, operating cash flow −$15.9M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $75.7M | -6% | +12% |
| Operating profit | −$10.7M | — | — |
| Net earnings | −$10.9M | — | — |
| Operating cash flow | −$15.9M | -185% | — |
What changed
Revenue was $75.7M in Q1 FY26, up 12% year over year and down 6% from the previous quarter. Med Device was the largest line at 53% of revenue. Med Tech added $7.3M year over year (up 26%), 89% of the total change.
Gross margin was 55.3%, up 0.9 points from a year earlier. Operating costs exceeded revenue by $10.7M, an operating margin of -14.1%. Operating expenses grew 5% against revenue growth of 12%. The fastest-growing cost line was General & admin (+14%). The quarter ended with a net loss of $10.9M, wider than the previous quarter's $6.0M loss.
Operating cash flow was −$15.9M. Non-cash charges added back $6.0M of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items used $15.4M. Capital expenditures of $731K exceeded it, leaving free cash flow of −$16.6M.
Questions
What was Angiodynamics' revenue in the first quarter fiscal 2026?
Angiodynamics (ANGO) reported revenue of $75.7M for the first quarter fiscal 2026 (Q1 FY26), +12% from a year earlier and -6% from the quarter before.
Was Angiodynamics profitable in the first quarter fiscal 2026?
Operating loss was $10.7M (-14.1% of revenue) and net loss $10.9M.
Source: Angiodynamics 10-Q on SEC EDGAR.